SCHEMBL608481

SCHEMBL608481

CC(C)(C)c1ccc(CN2CCN(CC(O)Cn3c4ccc(Br)cc4c4cc(Br)ccc43)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BAX Q07812 2/20 0.61
MAPT P10636 4/20 0.60
MAPK1 P28482 3/20 0.60
TP53 P04637 2/20 0.60
CYP3A4 P08684 1/20 0.60
ALOX15 P16050 1/20 0.60
RAD52 P43351 2/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
LMNA P02545 4/20 0.54
GAA P10253 1/20 0.54
HTT P42858 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
DNM1 Q05193 5/20 0.50
NLRP1 Q9C000 1/20 0.48
GPR183 P32249 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607481 0.95 MEN1 (0.67) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL610266 0.90 BAX (0.60) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL5022852 0.86 BAX (0.63) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL605835 0.86 BAX (0.63) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL605834 0.86 BAX (0.63) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL607023 0.86 LMNA (0.73) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL605724 0.86 MAPK1 (0.72) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL605725 0.86 MAPK1 (0.72) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL5022683 0.86 MAPK1 (0.72) BAXMAPTMAPK1TP53CYP3A4
SCHEMBL607410 0.86 MEN1 (0.66) BAXMAPTMAPK1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US claimed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD BAX 2/4885MAPT 1085/4885MAPK1 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.